Skip to main content
Top
Published in: Acta Diabetologica 5/2016

01-10-2016 | Original Article

Effectiveness of insulin glargine in type 2 diabetes mellitus patients failing glycaemic control with premixed insulin: Adriatic countries data meta-analysis

Authors: Maja Cigrovski Berkovic, Goran Petrovski, Natasa Grulovic

Published in: Acta Diabetologica | Issue 5/2016

Login to get access

Abstract

Aims

Type 2 diabetes mellitus (T2DM) is a progressive disease, often requiring exogenous insulin therapy and treatment intensification. Despite new therapies, most patients do not reach the recommended HbA1c targets, among them a significant proportion of patients on premixed insulins. The aim was to summarize published data in Adriatic countries on effectiveness of insulin glargine based therapy in type 2 diabetic patients suboptimally controlled on premix insulin.

Methods

A meta-analysis was carried out in major medical databases up to April 2014, focusing on Adriatic region. We searched observational studies with duration of at least 6 months, evaluating effectiveness and safety of insulin glargine (IGlar), in combination with OAD or bolus insulin in patients with T2 failing premixed insulin therapy. Outcomes included values of HbA1c, fasting blood glucose and two hours post-prandial glucose concentration as well as changes in body mass index after at least 6 months of study duration.

Results

Three prospective, observational, multicentric trials (698 patients in total) were included. The basal bolus regimen with glargine significantly reduced HbA1c (Mean Difference, MD=2.27, CI [1.76, 2.78]), fasting glucose (MD=5.15, CI [4.86, 5.44]) and 2-hours postprandial glucose concentration (MD=6.94, CI [6.53, 7.34]). No significant changes were found in BMI after switching from premixes to IGlar based treatment.

Conclusion

Insulin glargine based therapy following premix failure is efficacious and safe option of type 2 diabetes treatment intensification.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chen L, Magliano DJ, Zimmet PZ (2012) The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol 8:228–236CrossRef Chen L, Magliano DJ, Zimmet PZ (2012) The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol 8:228–236CrossRef
3.
go back to reference Monami M, Ragghianti B, Zannoni S, Vitale V, Nreu B, Mannucci E (2016) Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies. Acta Diabetol 53:35–40CrossRefPubMed Monami M, Ragghianti B, Zannoni S, Vitale V, Nreu B, Mannucci E (2016) Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies. Acta Diabetol 53:35–40CrossRefPubMed
4.
go back to reference Lavernia F (2011) What options are available when considering starting insulin: premix or basal? Diabetes Technol Ther 13(Suppl 1):S85–S92PubMed Lavernia F (2011) What options are available when considering starting insulin: premix or basal? Diabetes Technol Ther 13(Suppl 1):S85–S92PubMed
5.
go back to reference Tibaldi JM (2011) Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes. Clin Ther 33(11):1630–1642CrossRefPubMed Tibaldi JM (2011) Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes. Clin Ther 33(11):1630–1642CrossRefPubMed
6.
go back to reference Korytkowski M (2002) When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 26:S18–S24CrossRefPubMed Korytkowski M (2002) When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 26:S18–S24CrossRefPubMed
7.
go back to reference Bellia A, Babini AC, Marchetto PE, Arsenio L, Lauro D, Lauro R (2014) Effects of switching from NPH insulin to insulin glargine in patients with type 2 diabetes: the retrospective, observational LAUREL study in Italy. Acta Diabetol 51:269–275CrossRefPubMed Bellia A, Babini AC, Marchetto PE, Arsenio L, Lauro D, Lauro R (2014) Effects of switching from NPH insulin to insulin glargine in patients with type 2 diabetes: the retrospective, observational LAUREL study in Italy. Acta Diabetol 51:269–275CrossRefPubMed
8.
go back to reference Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S (2008) Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 31:20–25CrossRefPubMed Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S (2008) Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 31:20–25CrossRefPubMed
9.
go back to reference Roach P, Trautmann M, Arora V, Sun B, Anderson J (1999) Improved postprandial blood glucose control and reduced nocturnal hypoglycaemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and Insulin Lispro Mix50. Clin Ther 21:523–534CrossRefPubMed Roach P, Trautmann M, Arora V, Sun B, Anderson J (1999) Improved postprandial blood glucose control and reduced nocturnal hypoglycaemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and Insulin Lispro Mix50. Clin Ther 21:523–534CrossRefPubMed
10.
go back to reference Koivisto VA, Tuominen JA, Ebeling P (1999) Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 22:459–462CrossRefPubMed Koivisto VA, Tuominen JA, Ebeling P (1999) Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 22:459–462CrossRefPubMed
11.
go back to reference Garber et al (2006) 2006 Premixed Insulin Analogues for the Treatment of Diabetes Mellitus. Drugs 66(1):31–49CrossRefPubMed Garber et al (2006) 2006 Premixed Insulin Analogues for the Treatment of Diabetes Mellitus. Drugs 66(1):31–49CrossRefPubMed
12.
go back to reference Holman RR, Farmer AJ, Davies MJ et al (2009) Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl Med 361:1736–1747CrossRef Holman RR, Farmer AJ, Davies MJ et al (2009) Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl Med 361:1736–1747CrossRef
13.
go back to reference Schiel R, Schweitzer MA, Muller UA (2003) Quality of glycemic control and well-being of patients with type 2 diabetes mellitus after switching from conventional insulin therapy to once-daily insulin glargine in combination with oral anti-diabetic drugs—SWITCH pilot, a prospective randomized trial. Diabetologia 46:A272 (Abstract788) Schiel R, Schweitzer MA, Muller UA (2003) Quality of glycemic control and well-being of patients with type 2 diabetes mellitus after switching from conventional insulin therapy to once-daily insulin glargine in combination with oral anti-diabetic drugs—SWITCH pilot, a prospective randomized trial. Diabetologia 46:A272 (Abstract788)
14.
go back to reference Hammer H, Schneider K, Niemoller E, Schweitzer MA (2005) Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral agents on glycemic control in daily practice. Diabetes 54:518 (Abstract 2153) Hammer H, Schneider K, Niemoller E, Schweitzer MA (2005) Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral agents on glycemic control in daily practice. Diabetes 54:518 (Abstract 2153)
15.
go back to reference Zjacic V et al (2012) Efficacy and safety of a basal-bolus regimen with insulin glargine in patients with type 2 diabetes after failing pre-mix insulin therapy: a multicentre postmarketing study. Diabetol Croat 41(1):41-48 Zjacic V et al (2012) Efficacy and safety of a basal-bolus regimen with insulin glargine in patients with type 2 diabetes after failing pre-mix insulin therapy: a multicentre postmarketing study. Diabetol Croat 41(1):41-48
16.
go back to reference Buturovic et al (2013) Improved glycemic control with insulin glargine as part of basal bolus in regimen T2DM inadequately controlled on premixed therapy. Med Arh 67(5):342–345CrossRef Buturovic et al (2013) Improved glycemic control with insulin glargine as part of basal bolus in regimen T2DM inadequately controlled on premixed therapy. Med Arh 67(5):342–345CrossRef
17.
go back to reference Pemovska et al (2014) Mac. Evaluation of the effectivness and safety of basal based therapy with insulin glargine and prandial inaulin in patients with Type 2 diabetes poorly controlled with premixed insulins. Med Rev 68(1):44–48 Pemovska et al (2014) Mac. Evaluation of the effectivness and safety of basal based therapy with insulin glargine and prandial inaulin in patients with Type 2 diabetes poorly controlled with premixed insulins. Med Rev 68(1):44–48
18.
go back to reference Pešić M, Živić S, Radenković S, Velojić M, Dimić D, Antić S (2007) Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy. Vojnosanit Pregl 64(4):247–252CrossRefPubMed Pešić M, Živić S, Radenković S, Velojić M, Dimić D, Antić S (2007) Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy. Vojnosanit Pregl 64(4):247–252CrossRefPubMed
19.
go back to reference Damnjanović I, Veličković-Radovanović R, Kocić R, Zlatković-Guberinić S, Sokolović D, Đinđić N, Conić I (2011) Influence of beta-blockers on insulin resistance in patients with diabetes mellitus type 2. Acta Med Median 50(4):23–28CrossRef Damnjanović I, Veličković-Radovanović R, Kocić R, Zlatković-Guberinić S, Sokolović D, Đinđić N, Conić I (2011) Influence of beta-blockers on insulin resistance in patients with diabetes mellitus type 2. Acta Med Median 50(4):23–28CrossRef
20.
go back to reference Damnjanovic I, Velickovic-Radovanovic R, Catic-Djordjevic A, Kocic R, Ciric V, Conic I, Bjelakovic LJ (2008) Pharmacokinetic and pharmacodynamic modelling of base insulins and analogs. Acta Med Median 47(4):15–19 Damnjanovic I, Velickovic-Radovanovic R, Catic-Djordjevic A, Kocic R, Ciric V, Conic I, Bjelakovic LJ (2008) Pharmacokinetic and pharmacodynamic modelling of base insulins and analogs. Acta Med Median 47(4):15–19
21.
go back to reference Davies M, Sinnassamy P, Fred Storms F et al (2008) Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res and Clin Pract 79:368–375CrossRef Davies M, Sinnassamy P, Fred Storms F et al (2008) Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res and Clin Pract 79:368–375CrossRef
22.
go back to reference Fritsche A, Larbig M, Owens D, Haring HU (2010) Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes—results of the GINGER study. Diabetes Obes Metab 12:115–123CrossRefPubMed Fritsche A, Larbig M, Owens D, Haring HU (2010) Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes—results of the GINGER study. Diabetes Obes Metab 12:115–123CrossRefPubMed
23.
go back to reference Qayyum R, Bolen S, Maruthur N et al (2008) Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 149:549–559CrossRefPubMedPubMedCentral Qayyum R, Bolen S, Maruthur N et al (2008) Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 149:549–559CrossRefPubMedPubMedCentral
26.
go back to reference Review Manager (RevMan) [Computer program] (2012) Version 5.2. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen Review Manager (RevMan) [Computer program] (2012) Version 5.2. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen
Metadata
Title
Effectiveness of insulin glargine in type 2 diabetes mellitus patients failing glycaemic control with premixed insulin: Adriatic countries data meta-analysis
Authors
Maja Cigrovski Berkovic
Goran Petrovski
Natasa Grulovic
Publication date
01-10-2016
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 5/2016
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-016-0861-1

Other articles of this Issue 5/2016

Acta Diabetologica 5/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.